Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px
Document › Details

BiondVax Pharmaceuticals Ltd.. (9/13/17). "Press Release: BiondVax Announces Public Offering of American Depositary Shares". Ness Ziona.

Region Region United States (USA)
Organisations Organisation BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV)
  Organisation 2 Joseph Gunnar & Co., LLC
Products Product M-001 universal flu vaccine (BiondVax)
  Product 2 investment banking
Index term Index term BiondVax–SEVERAL: investment, 201709 Pulbic Offering $10m w 1.5m+166.7k ADSs at $6/ADS
Persons Person Babecoff, Ron (BiondVax 201709 CEO)
  Person 2 Phillipson, Joshua (BiondVax 201707 Business Development Manager)
     


BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced that it intends to offer for sale its American Depositary Shares (“ADS”), each representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each).

All of the ADSs in the offering are being offered by BiondVax. The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering.

Joseph Gunnar & Co., LLC is acting as the sole book-running manager for the offering.

The ADSs described above will be issued pursuant to a registration statement on Form F-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on December 15, 2016. The securities may be offered only by means of a prospectus and related prospectus supplement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and will be available on the SEC’s website at http://www.sec.gov.

Before buying any of BiondVax’s ADSs in the offering, investors should carefully read the preliminary prospectus supplement and the accompanying prospectus, together with the information incorporated by reference therein. These documents contain important information that investors should consider when making their investment decisions. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these ADSs may be obtained by contacting Joseph Gunnar & Co., LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: prospectus@jgunnar.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.


About BiondVax

BiondVax is a biopharmaceutical company developing M-001, a universal flu vaccine candidate. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.


Contact Details

Joshua Phillipson
Business Development
+972 8 930 2529
j.phillipson@biondvax.com


Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the results of the contemplated Phase 2 & 3 trials, delays or obstacles in launching and/or successfully completing our clinical trials, the impact of the global economic environment on the Company customer target base, the adequacy of available cash resource and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC’s website, www.sec.gov, and in the Company’s periodic filings with the SEC and the Tel-Aviv Stock Exchange.

   
Record changed: 2017-09-21

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px